Yes, it's Trump's fault
The prosecution's case: Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The extreme prosecution of the sourced event.
Case C0413D783D37FB55406B · 2026-11-10
The Trump Jury
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
Read both sides. Cast your verdict. Predict the crowd.
- 1 Case
- 2 Verdict
- 3 Prediction
- 4 Results
Step 1
Read the case
Neutral facts
The US FDA mandates that Ozempic and Wegovy include warnings about NAION.
What the record shows: The FDA's order requires updated labeling for certain drugs.
ProsecutionSatire
The prosecution's case: Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The extreme prosecution of the sourced event.
Read the full prosecution
DefenseSatire
The defense's case: Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The extreme defense of the sourced event.
Read the full defense
The Result
Supporters might argue that the FDA's decision to mandate warnings about NAION on Ozempic and Wegovy is a testament to the government's commitment to patient safety. The defense submits that this proactive measure reflects a responsible approach to public health.
What Trump Did
The defense might suggest that under Trump's administration, there was a significant focus on addressing obesity through innovative treatments like GLP-1 drugs. The defense admits that while these drugs have been effective for many, the inclusion of warnings is a necessary step to ensure transparency.
Why Supporters Credit Him
Supporters might argue that the availability of these medications has empowered individuals to take control of their health, leading to better outcomes. The defense might argue that the FDA's actions are a recognition of the importance of monitoring drug safety.
The Supporting Record
The defense submits that the rise in popularity of these drugs has coincided with a national dialogue about obesity and health, which Trump helped to elevate.
The Limitation or Competing Explanation
However, the defense might argue that while the warnings are important, they should not overshadow the positive impact these drugs have had on many lives.
Verdict
If this is Trump's fault, his supporters will gladly let him take the blame.
Defense exhibits
- Supporters' theory: FDA prioritizes patient safety.
- Supporters' theory: GLP-1 drugs empower health choices.
- Supporters' theory: National dialogue on obesity improves outcomes.
Reality Check
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
Satirical commentary based on the sourced facts above. Not a news report, campaign, or endorsement.
Connecting to the jury room…
Final verdict announced: November 11, 2026 at 5:01 PM ET
Step 2 · Personal verdict
Your verdict
Cast your verdict in the POLL above. Then predict the jury here.
No account required. One active verdict per browser; you can change it while voting is open.
Step 3 · Crowd prediction
Predict the jury
When this case closes, what percentage of readers will say “Trump’s fault”?
Step 4 · Reader verdict
Poll
All Responses
Live0 verified votes
Yes, it's Trump's fault
0%
No, it's not Trump's fault
0%
Too soon to tell
0%
- Your verdict
- —
- Your prediction
- —
Only 0 points away
100Accuracy score
Results are based on participating site visitors and are not a scientific poll.
Voting closed
Step 5 · Challenge your friends
Can you beat my prediction?
Your jury record
This browser
- Cases judged
- 0
- Average accuracy
- —
- Current streak
- 0
Opening Argument
The prosecution argues that the recent FDA mandate to include warnings about NAION on Ozempic and Wegovy is a direct consequence of the reckless policies championed by Trump. The prosecution alleges that these weight-loss drugs, while marketed as solutions to obesity, are actually part of a larger scheme to distract the public from the administration's failures.
Exhibit A: The Plausible Link
The prosecution submits that the rise in prescriptions for these drugs correlates with the Trump administration's push for deregulation in the pharmaceutical industry.
The Domino Effect
The prosecution imagines a scenario where patients, lured by the promise of weight loss, are now facing the terrifying prospect of blindness.
The Hidden Danger
The prosecution urges that the true danger lies not just in the drugs themselves, but in the culture of negligence fostered by Trump’s policies.
Closing Argument
In the prosecution's theory, the FDA's warning is merely a band-aid on a much larger wound inflicted by the former president's administration.
Verdict
The prosecution urges that we must hold Trump accountable for the consequences of his policies, which have led us to this alarming situation.
Prosecution exhibits
Reality Check
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.